ImmunityBio
IBRX
IBRX
125 hedge funds and large institutions have $390M invested in ImmunityBio in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 17 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
59% less call options, than puts
Call options by funds: $8.17M | Put options by funds: $19.9M
Holders
125
Holding in Top 10
1
Calls
$8.17M
Puts
$19.9M
Top Buyers
| 1 | +$42.8M | |
| 2 | +$26.6M | |
| 3 | +$24.6M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$12.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.5M |
Top Sellers
| 1 | -$2.34M | |
| 2 | -$2.23M | |
| 3 | -$1.95M | |
| 4 |
Rafferty Asset Management
New York
|
-$1.54M |
| 5 |
LPL Financial
San Diego,
California
|
-$1.52M |